Scarica l'app Stockscreener
17.71
1.19%
0.2074
Bausch Lomb Corp Borsa (BLCO) Ultime notizie
Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Target Price at $20.25 - MarketBeat
Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 - GlobeNewswire Inc.
Bausch Lomb Corporation (BLCO-T) QuotePress Release - The Globe and Mail
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 - Business Wire
This Bausch + Lomb Insider Increased Their Holding In The Last Year - Yahoo Finance
Ellsworth Advisors LLC Invests $665,000 in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Wells Fargo & Company Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $24.00 - Defense World
Bausch + Lomb bolsters pipeline with acquisition of Whitecap Biosciences - ROI-NJ.com
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences - BioSpace
Bausch + Lomb Launches enVista Aspire IOLs in Europe - TipRanks
Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union - Business Wire
Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20? - Yahoo Finance
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine - Yahoo Finance
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy - Yahoo Finance
Implantable Drug Delivery Devices Business Research Report 2023-2024 & 2030 - GlobeNewswire Inc.
S&P 500 Futures Rise in Premarket Trading; Aurora Innovation, Bausch + Lomb Lead - Barron's
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge - Business Wire
Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Shares Acquired by State Street Corp - Defense World
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Warburg Pincus to buy Bausch & Lomb for $3.67 bln - Reuters
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - Yahoo Finance
Bausch + Lomb down after report that Blackstone could back away from takeover bid - MSN
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Y Intercept Hong Kong Ltd Makes New Investment in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Rises By 11.7% - MarketBeat
Janus Henderson Group PLC Purchases New Shares in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch And Lomb Says Potential Sale In The Works - Law360
Bausch + Lomb exploring several options including a potential sale - Coast Reporter
Contact lens maker Bausch + Lomb says it is exploring sale - Reuters
Bausch + Lomb confirms it is exploring a potential sale - Financial Post
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):